Priyanka Grover
Stock Analyst at J.P. Morgan
(0.23)
# 4,496
Out of 4,685 analysts
16
Total ratings
38.5%
Success rate
-25.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Priyanka Grover
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group | Downgraded: Sell | n/a | $0.272 | - | 8 | Aug 18, 2026 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $13 | $6.99 | +85.98% | 1 | Aug 18, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $31 | $19.42 | +59.63% | 3 | Aug 14, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Rated: Buy | $25 | $9.18 | +172.33% | 1 | Aug 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $146 | $112.53 | +29.74% | 1 | Aug 10, 2026 | |
| RXRX Recursion Pharmaceuticals | Maintained: Buy | $11 → $10 | $3.44 | +190.70% | 2 | Apr 30, 2026 |
Mereo BioPharma Group
Aug 18, 2026
Downgraded: Sell
Price Target: n/a
Current: $0.272
Upside: -
Nuvation Bio
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $6.99
Upside: +85.98%
Relay Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $31
Current: $19.42
Upside: +59.63%
BridgeBio Oncology Therapeutics
Aug 14, 2026
Rated: Buy
Price Target: $25
Current: $9.18
Upside: +172.33%
Rhythm Pharmaceuticals
Aug 10, 2026
Reiterated: Buy
Price Target: $146
Current: $112.53
Upside: +29.74%
Recursion Pharmaceuticals
Apr 30, 2026
Maintained: Buy
Price Target: $11 → $10
Current: $3.44
Upside: +190.70%